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INTRODUCTION
The morbidity, mortality, and costs associated with asthma 
are imposing an ever increasing burden on society. Evidence 
obtained worldwide indicates that health care costs related to 
asthma represent a large percentage of health care expendi-
tures.
1-7 Nevertheless, little reliable information is available re-
garding the nature and magnitude of the burden imposed by 
asthma at the national level in the Republic of Korea. Further-
more, the lack of a unified health care system means that nation-
wide surveys are not feasible, and as a result, the majority of 
previous estimations were based on secondary data, expert 
opinions, or small-scale surveys.
1-3,5,6 Consequently, estimations 
of the cost of asthma vary widely.
8
Owing to the chronic and incurable, but not life-threatening, 
nature of asthma, one goal of asthma control is improving qual-
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ity of life (QOL).
9,10 The use of complementary and alternative 
medicines (CAMs) is common among asthmatics,
11 ranging 
from 33% to 51% of asthmatics in Europe.
12-14 However, the true 
economic impact of impaired QOL in asthmatics and the amount 
spent on CAMs beyond the official health care system have not 
been properly estimated.
The present study was undertaken to determine the financial 
burden of asthma in the Republic of Korea, where enrollment 
in the National Health Insurance Corporation [NHIC, a single 
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Purpose:  Asthma-related morbidity and mortality are increasing, and the financial burden imposed by this condition will substantially increase. 
Nevertheless, little information is available regarding the nature and magnitude of the burden due to asthma at the national level. This study was 
conducted to characterize the financial burden imposed by asthma in the Republic of Korea at the national level.  Methods:  The overall prevalence 
of asthma and the costs of related medical services were determined using data from the National Health Insurance Corporation, which is responsi-
ble for the National Health Insurance scheme. Indirect costs, including expenditures on complementary and alternative medicines, and the financial 
impact of an impaired quality of life (intangible costs) were estimated by surveying 660 asthmatics, and these estimates were transformed to the 
national level using the prevalence of asthma.  Results:  The prevalence of asthma and total costs related to the disease in 2004 were 4.19% and 
$2.04 billion, respectively. Direct costs and indirect costs contributed equally to total costs (46.9% and 53.1%, respectively). However, when intangi-
ble costs were included, total costs rose to $4.11 billion, which was equivalent to 0.44% of the national gross domestic product in 2004.  Conclu-
sions:  The results provide evidence that asthma is a major health cost factor in the Republic of Korea and that intangible costs associated with 
asthma are significant cost drivers.
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payer for National Health Insurance (NHI)] is compulsory; thus, 
the NHIC covers the whole nation.
15 The main sources of the in-
formation used in this study were health insurance claims data 
from the NHIC, which enabled us to estimate the nationwide 
financial burden of asthma. We also estimated the economic 
impact of impaired QOL (intangible costs) using the willingness-
to-pay (WTP) method and the amount spent on CAMs. To our 
knowledge, this is the first estimate of the economic impacts of 
impaired QOL and CAMs related to asthma at the national lev-
el in the Republic of Korea.
 
MATERIALS AND METHODS
Asthma prevalence
We identified subjects with asthma as a main diagnosis by 
searching the NHIC data base for codes J45 and J46 of the Inter-
national Classification of Diseases-Tenth Revision (ICD-10)
16 
associated with any medical event (i.e., hospitalization, office/
clinic visit, emergency room visit, or pharmacy visit). We then 
analyzed insurance claim data for the period 1 January to 31 
December 2003 to determine asthma prevalence.
Patient survey
Asthma was diagnosed and its severity was determined based 
on spirometry results, in accordance with international guide-
lines.
17 All patients with asthma were randomly recruited by al-
lergy specialists who were chosen to represent a range of profes-
sional (university, general, and private clinics) and geographical 
(metropolitan and non-metropolitan) settings throughout the 
Republic of Korea. At the initial visit, the patient, or the patient’s 
parent for patients younger than 15 years of age, completed a 
questionnaire that addressed demographic factors, disease-re-
lated variables (symptom severity, current medication, and co-
morbid conditions), and cost-related variables (recall of medi-
cal service usage, expenditure on CAMs, WTP questionnaires, 
and work loss due to asthma over the previous 12 months). Pa-
tients were asked to keep a diary and record absences from school 
or work, medical services usage, and expenditures related to 
asthma management for 3 months (from 1 April to 30 June 2004). 
This prospective evaluation was designed to determine the ex-
tent to which recall bias affected questionnaire responses. All 
patients enrolled in this study provided written informed con-
sent.
Costs of asthma
Asthma-related costs were estimated as prevalence-based 
costs (the cross-sectional costs of all patients per annum) in 
2004. All costs are presented in U.S. dollars calculated using the 
exchange rate for 30 April 2005: 1 U.S. dollar = 1,000 Korean won 
(\). Costs before 2004 were extrapolated to 2004 values using 
the inflation rate of the field-specific price. The cost and source 
categories for the estimates are presented schematically in Ta-
ble 1.
Direct formal medical costs
Direct formal medical costs were defined as the amounts ex-
pended on asthma management within the official health care 
system and included reimbursed and non-reimbursed costs. 
Reimbursed costs were payments for ambulatory care visits, 
hospital outpatient services, hospital inpatient stays, emergen-
cy room visits, physician and facility services, and prescribed 
medicines. These were extracted from NHIC data for the period 
1 January to 31 December 2003 and included payments claimed 
by oriental medicine hospitals, which are regarded as part of 
the official health care system. Sometimes, because of stringent 
benefit coverage, patients paid a substantial sum for uninsured 
(out-of-coverage) services.
15 For example, patients must pay in 
full for uninsured services such as meals during hospitalization 
and private rooms (rooms with fewer than six beds). In the pres-
ent study, these were collectively categorized as non-reimbursed 
costs. The ratio of reimbursed to non-reimbursed costs derived 
from the patient survey was multiplied by the total amount of 
reimbursed costs calculated from NHIC data.
Direct informal medical and non-medical costs
Direct informal medical costs were defined as expenditures 
on CAMs not recompensed by the official health care system. 
Direct non-medical costs were defined as expenditures on med-
ical-related services such as transport to the hospital and private 
nursing personnel. These costs were obtained by patient survey. 
A geometric mean value was calculated from the mean values 
of three age groups: elderly, ≥65 years old; adults, 20-64 years 
old; and children, ≤19 years old. These values were extended to 
the national level by multiplying by the total number of patients 
with asthma.
Table 1.  Asthma cost categories and resources used for estimation
Category Direct formal medical Direct informal medical Direct non-medical  Indirect Intangible
Sub-category Reimbursed 
(patient + insurer)
Non-reimbursed CAMs Traffic Time loss QOL
Nursing Death
Data sources NHIC data Patient survey Patient survey Patient survey & 
NHIC data
Patient survey & 
NHIC data
Patient survey
(WTP)
CAMs, complementary and alternative medicines; QOL, quality of life; NHIC, National Health Insurance Corporation; WTP, willingness-to-pay.Kim et al.
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Indirect costs
Indirect costs were defined as costs incurred due to asthma-
related loss of work and premature death. To estimate the costs 
of asthma-related loss of work, the average number of absences 
per patient or caregiver as a result of admission, ambulatory vis-
its, and care was obtained from the patient survey, and this num-
ber was multiplied by age- and gender-specific wages and em-
ployment rates. The costs of asthma-related premature death 
were estimated using the calculated number of asthma-related 
deaths in 2004 and the expected future income based on demo-
graphic characteristics.
Intangible costs
Enrolled patients responded to a QOL questionnaire, devel-
oped by the Korean Society of Allergology,
18 using a five-point 
scale to assess current QOL parameters. The patients also an-
swered WTP questionnaires, which were designed as a bidding 
game. Patients were each allocated six different random bids, 
and after responding to yes-or-no questions twice, the patients 
were asked to evaluate their final WTP to improve their QOL. We 
used only half of the WTP estimates, because the WTP method 
generally provides an overestimation.
19 Individually measured 
costs were transformed to the national level by using asthma 
prevalence.
 
RESULTS
The overall prevalence of asthma in the Republic of Korea in 
2004 was 4.19%, based on NHIC data. Prevalence rates by age 
group are shown in Table 2. A total of 660 asthma patients from 
31 institutions (18 in urban areas, 13 in rural areas) were enrolled 
in the patient survey. These included 180 elderly asthmatics (≥65 
years old), 350 adult asthmatics (20-64 years old), and 130 child 
asthmatics (≤19 years old). Among these, 314 (47.8%) were male. 
According to asthma severity, 470 patents (71.2%) were catego-
rized with mild asthma; 130 (19.7%), with moderate asthma; 
and 60 (9.1%), with severe asthma.
Costs of asthma
The total direct asthma-related cost in the Republic of Korea 
in 2004 was approximately $961.9 million. The estimated direct 
formal medical cost of asthma was $333.4 million in 2004. The 
largest portion was attributable to medication (35.3%), followed 
by ambulatory visits and hospitalization (Table 3). Direct infor-
mal medical costs amounted to $622.8 million and accounted 
for 64.7% of total direct medical costs. The direct formal and in-
formal medical costs per patient per annum were $162.20 and 
$302.80, respectively. Direct non-medical costs were estimated 
to be $5.7 million, and these were mainly incurred by transpor-
Table 2.  Prevalence of asthma by age
Age group (yr)
Prevalence (%)
Total Male Female
0 - 4 23.68 25.28 21.94
5 - 9 10.86 11.23 10.45
10 - 14 3.08 3.48 2.63
15 - 19 1.11 1.11 1.11
20 - 24 0.95 0.66 1.26
25 - 29 1.38 0.85 1.94
30 - 34 1.90 1.17 2.66
35 - 39 1.95 1.38 2.55
40 - 44 2.02 1.43 2.63
45 - 49 2.30 1.64 2.98
50 - 54 2.80 2.06 3.55
55 - 59 3.62 2.80 4.42
60 - 64 4.71 3.98 5.37
65 - 69 6.00 5.64 6.30
70 - 74 7.20 7.39 7.07
> 75  7.65 8.64 7.16
Overall prevalence 4.19 3.92 4.47
Table 3.  Estimated direct costs of asthma in 2004
Cost category Cost ($)* %
Formal medical 333.4 34.7
Medication 117.8 35.3
†
Ambulatory visit
To general practitioner 110.4 33.1
†
To specialist 48.5 14.6
†
Hospitalization 56.1 16.8
†
Oriental medicine 0.6 0.2
†
Informal medical 622.8 64.7
Non-medical 5.7 0.6
Total 961.9 100.0
*In millions; 
†percentage to the formal medical costs.
Table 4.  Estimated indirect costs of asthma in 2004
Cost category
Sensitivity analysis
Excluding the elderly* Including the elderly
Cost ($)
† % Cost ($)
† %
Loss of productivity 
as a patient
1,085.2 99.9 1,180.5 99.9
Due to ambulatory visit 60.1 5.5
‡ 68.3 5.7
‡
Due to admission 6.2 0.6
‡ 9.7 0.9
‡
Due to absence or early 
leave
952.5 87.8
‡ 1036.1 87.8
‡
Due to premature death 66.4 6.1
‡ 66.4 5.6
‡
Loss of productivity 
as a caregiver
1.2 0.1 1.2 0.1
Total 1,086.4 100.0 1,181.7 100.0
*Age ≥65 years; 
†In millions; 
‡Percentage of lost productivity of patients.Financial Burden of Asthma in Korea AAIR 
Allergy Asthma Immunol Res. 2011 January;3(1):34-38.  doi: 10.4168/aair.2011.3.1.34 37 http://e-aair.org
tation.
Total costs for asthma-related loss of productivity for patients 
and caregivers in 2004 were estimated to be $1.18 billion and 
$66.4 million, respectively (Table 4). Up to 90% of lost produc-
tivity was attributable to absence or early leave from work. Indi-
vidual asthmatics were willing to pay about $151.90 monthly to 
improve QOL up to a “normal” level. Intangible costs were esti-
mated to be $2.06 billion, almost the same as the sum of the di-
rect and indirect costs.
The total costs for asthma in 2004 are summarized by category 
in Table 5. The total cost of asthma, excluding intangible costs, in 
2004 was $2.04 billion, 46.9% of which were direct costs and 
53.1% of which were indirect costs. When intangible costs were 
included, total costs doubled to $4.11 billion, which is equiva-
lent to 0.44% of the gross domestic product of the Republic of 
Korea in 2004
20 and 85.7% of all governmental social security 
expenditures in 2003.
Sensitivity analysis
A sensitivity analysis was conducted to evaluate the robustness 
of the cost estimates when key assumptions were modified. It 
was believed that productivity loss due to asthma in the elderly 
group (≥65 years old) was minimal. However, the prevalence of 
asthma in the elderly is exceptional (12.7% in 2001
21), and life 
expectancy is 75.4 years for men and 82.2 years for women.
20 
Thus, we performed a sensitivity test to evaluate the economic 
impact of productivity loss in the elderly. Contrary to our ex-
pectations, the loss of productivity due to asthma in the elderly 
had a considerable effect, accounting for $95.3 million (8.8%) of 
the indirect costs (Table 4). This amount was nearly twice the 
direct medical costs of hospitalization in the elderly.
 
DISCUSSION
The overall prevalence of asthma and the total costs related to 
asthma in 2004 were 4.19% and $2.04 billion, respectively, in the 
Republic of Korea. Direct and indirect costs contributed equally 
to total costs (46.9% and 53.1%, respectively). Furthermore, when 
intangible costs were included, the total cost increased to $4.11 
billion, which is nearly equivalent to 0.44% of the gross domes-
tic product in 2004.
The present study was performed using NHIC data, which has 
both advantages and disadvantages. Since 2000, the health in-
surance system in the Republic of Korea has provided coverage 
for the entire population.
22 Under this system, all medical costs 
incurred for prescriptions, hospital admissions, and ambulato-
ry visits are reimbursed by the NHIC. Thus, NHIC data provide 
nationwide, comprehensive estimates of disease-related costs, 
which cannot be acquired by secondary analysis of data or small-
scale surveys. However, there are some concerns regarding NHIC 
data, particularly the possible misclassification of asthma listed 
as J45 or J46. For example, in children younger than 10 years of 
age, a wheezing episode caused by a non-asthmatic condition 
such as bronchiolitis is frequently diagnosed as asthma. Accord-
ingly, this may limit the generalization of our results. Neverthe-
less, whether or not those listed by the NHIC as J45 or J46 were 
actually asthmatics, the estimated costs in this study represent 
the financial burden imposed on society by those diagnosed as 
having asthma. Thus, the estimations provide valuable infor-
mation regarding health service planning.
Direct costs are usually determined by disease severity, medi-
cation compliance, overall prevalence of a disease, and health 
care costs. For example, in the US in 1994, direct costs represent-
ed the majority (88%) of the total costs, while indirect costs com-
prised only 12%, because health care costs are higher in the US.
23 
The health insurance system in the Republic of Korea relies on 
a fee scheduling system for reimbursement of health care pro-
viders, and the government scrupulously regulates this system, 
to the extent that reimbursements at best barely cover the cost 
of providing medical care.
15 This regulated fee-for-service sys-
tem is probably one reason for the difference in the proportion 
of direct costs between the US and the Republic of Korea.
Although many reports have mentioned the high prevalence 
of CAMs among asthmatics,
11-13,24 little information is available 
regarding the costs at the national level. Surprisingly, the total 
expenditure on CAMs for asthmatics, presented as direct infor-
mal medical costs in the present study, was almost double the 
direct formal medical costs. Although there are undoubtedly na-
tional differences regarding individual methods and providers, 
CAMs for asthma should be recognized as a considerable cost 
burden on society and on individual patients.
One important challenge faced by those studying the financial 
burden of disease is how to precisely measure, value, and in-
corporate health-related QOL changes into an economic anal-
ysis. A cost-benefit analysis, also known as WTP, is one method 
of performing these evaluations. This type of analysis involves 
the use of survey techniques to elicit the amount of money an 
individual would be willing to pay for a specified health change. 
25,26 Zillich et al.
27 demonstrated that WTP for an asthma cure is 
related to both objective and subjective disease severity. The 
mean monthly WTPs were $90, $131, and $331 for individual 
mild, moderate, and severe asthmatics, respectively.
27 A similar 
trend was also found in the present study, but the differences 
by severity were smaller (the corresponding numbers were $137, 
Table 5.  Total costs of asthma in 2004
Cost category            Cost ($)*       %
Direct  0.96 46.9
†
Indirect 1.08 53.1
†
Direct + Indirect 2.04
Intangible 2.06
Total 4.11
*In billions; 
†Percentage of the sum of direct and indirect costs.Kim et al.
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$143, and $183). These findings suggest that some asthmatics 
in the Republic of Korea, although classified as mild by physi-
cians, have an unsatisfied desire for a better QOL, matching the 
desire of severe asthmatics. Overall, the economic impact of 
impaired QOL, presented as intangible costs in this study, was 
tremendous and almost as large as the sum of direct and indi-
rect costs.
The potential for cost savings based on reducing direct infor-
mal costs becomes readily apparent from our results. In this re-
gard, the public health implications of CAMs should be viewed 
in the context of the limited evidence of their efficacy and their 
huge financial burden. In addition, considering that the eco-
nomic impact of impaired QOL in asthmatics is as great as total 
asthma costs, improvements in QOL should be a goal of asthma 
control or a target of public programs for asthma care.
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